Related Experiment Video
Updated: Aug 11, 2026
07:26
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Novel targets for antithrombotic drug discovery
Nisha Nanda1, David R Phillips
1Portola Pharmaceuticals Inc., 270 E. Grand Avenue, South San Francisco, CA 94080, USA.
Blood Cells, Molecules & Diseases
|February 14, 2006
Summary
Platelet aggregation involves signaling molecules CD84, CD150 (SLAM), and PEAR1, which stabilize aggregates. These molecules may be targets for new antithrombotic drugs.
Area of Science:
- Hematology
- Molecular Biology
- Immunology
Background:
- Platelet aggregation is a complex process regulated by signaling cascades and secondary agonists.
- Homophilic adhesion molecules CD84 and CD150 (SLAM), and PEAR1 receptor are involved in platelet aggregation.
- These molecules are tyrosine-phosphorylated during platelet aggregation.
Purpose of the Study:
- To investigate the role of CD84, CD150 (SLAM), and PEAR1 in platelet aggregation and stability.
- To explore the potential of these molecules as targets for antithrombotic drug discovery.
Main Methods:
- Proteomics and genomics strategies were employed.
- Analysis of SLAM-deficient mice was performed to assess platelet aggregation in vitro and arterial thrombosis in vivo.
Main Results:
- CD84, CD150 (SLAM), and PEAR1 trigger signaling pathways during platelet aggregation.
- SLAM-deficient mice exhibited impaired platelet aggregation and delayed arterial thrombosis.
- These receptors may form a 'platelet synapse' to enhance aggregate stability.
Conclusions:
- CD84, CD150 (SLAM), and PEAR1 are crucial for platelet aggregation and stability.
- These receptors represent potential novel targets for developing antithrombotic therapies.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...